About Medicure
Medicure Inc. (Medicure) is a pharmaceutical company engaged in the research, clinical development and commercialization of human therapeutics. The Company operates in the biopharmaceutical industry segment. The Company's primary operating focus is on the sale and marketing of its acute care cardiovascular drug, AGGRASTAT (tirofiban hydrochloride) owned by its subsidiary, Medicure International, Inc. and distributed in the United States and its territories through the Company's United States subsidiary, Medicure Pharma, Inc. AGGRASTAT, a glycoprotein IIb/IIIa inhibitor (GPI), is used for the treatment of acute coronary syndrome (ACS). The Company is also engaged in the development of TARDOXAL for neurological disorders, such as Tardive Dyskinesia (TD). The Company has completed Phase IIa stage of development for TARDOXAL. The Company is also developing Transdermal AGGRASTAT, a cure for acute cardiology. Transdermal AGGRASTAT is in preclinical-stage of development.
Industry, Sector and Symbol:
- Sector: N/A
- Industry: N/A
- Sub-Industry: N/A
- Exchange: CVE
- Symbol: MPH
- CUSIP:
Key Metrics:
- Previous Close: $0.00
- 50 Day Moving Average: $N/A
- 200 Day Moving Average: $N/A
- 52-Week Range: C$3.00 - C$7.29
- Trailing P/E Ratio: N/A
- P/E Growth: N/A
- Market Cap: $N/A
- Outstanding Shares: 15,019,000
Additional Links:
Consensus Ratings for Medicure (CVE:MPH) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.| Ratings Breakdown: | 2 Buy Ratings |
| Consensus Rating: | Buy (Score: 3.00) |
| Consensus Price Target: | C$8.00 |
Analysts' Ratings History for Medicure (CVE:MPH)
Show:
| Date | Firm | Action | Rating | Price Target | Details |
|---|
| 5/4/2016 | M Partners | Reiterated Rating | Buy | |  |
| 1/12/2016 | Mackie | Boost Price Target | Buy | C$8.00 | |
(Data available from 9/29/2014 forward)
Earnings History for Medicure (CVE:MPH)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Medicure (CVE:MPH)Current Year EPS Consensus Estimate: $0.25 EPS
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2016 | 1 | $0.13 | $0.13 | $0.13 |
| Q2 2016 | 1 | $0.13 | $0.13 | $0.13 |
| Q3 2016 | 1 | $0.16 | $0.16 | $0.16 |
| Q4 2016 | 1 | $0.18 | $0.18 | $0.18 |
| Q1 2017 | 1 | $0.26 | $0.26 | $0.26 |
| Q2 2017 | 1 | $0.27 | $0.27 | $0.27 |
| Q3 2017 | 1 | $0.29 | $0.29 | $0.29 |
| Q4 2017 | 1 | $0.31 | $0.31 | $0.31 |
(Data provided by Zacks Investment Research)
Dividend History for Medicure (CVE:MPH)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Medicure (CVE:MPH)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 3/17/2016 | Albert David Friesen | Director | Buy | 1,100 | C$5.55 | C$6,105.00 | |
| 3/16/2016 | Graeme William Merchant | Insider | Buy | 1,650 | C$6.40 | C$10,560.00 | |
| 3/11/2016 | Graeme William Merchant | Insider | Buy | 1,500 | C$6.30 | C$9,450.00 | |
| 3/8/2016 | Graeme William Merchant | Insider | Sell | 6,300 | C$7.01 | C$44,163.00 | |
| 9/9/2015 | Elliott International Capital | Insider | Sell | 1,426,002 | C$2.98 | C$4,249,485.96 | |
| 1/7/2015 | Albert David Friesen | Director | Buy | 2,900 | C$2.01 | C$5,829.00 | |
(Data available from 1/1/2013 forward)
Latest Headlines for Medicure (CVE:MPH)
Medicure (CVE:MPH) Chart for Thursday, September, 29, 2016
